Document Detail

Outcome--adaptive randomization: is it useful?
MedLine Citation:
PMID:  21172882     Owner:  NLM     Status:  MEDLINE    
Outcome-adaptive randomization is one of the possible elements of an adaptive trial design in which the ratio of patients randomly assigned to the experimental treatment arm versus the control treatment arm changes from 1:1 over time to randomly assigning a higher proportion of patients to the arm that is doing better. Outcome-adaptive randomization has intuitive appeal in that, on average, a higher proportion of patients will be treated on the better treatment arm (if there is one). In both the randomized phase II and phase III settings with a short-term binary outcome, we compare outcome-adaptive randomization with designs that use 1:1 and 2:1 fixed-ratio randomizations (in the latter, twice as many patients are randomly assigned to the experimental treatment arm). The comparisons are done in terms of required sample sizes, the numbers and proportions of patients having an inferior outcome, and we restrict attention to the situation in which one treatment arm is a control treatment (rather than the less common situation of two experimental treatments without a control treatment). With no differential patient accrual rates because of the trial design, we find no benefits to outcome-adaptive randomization over 1:1 randomization, and we recommend the latter. If it is thought that the patient accrual rates will be substantially higher because of the possibility of a higher proportion of patients being randomly assigned to the experimental treatment (because the trial will be more attractive to patients and clinicians), we recommend using a fixed 2:1 randomization instead of an outcome-adaptive randomization.
Edward L Korn; Boris Freidlin
Publication Detail:
Type:  Journal Article     Date:  2010-12-20
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  29     ISSN:  1527-7755     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-02-18     Completed Date:  2011-04-01     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  771-6     Citation Subset:  IM    
Biometric Research Branch, EPN-8129, National Cancer Institute, Bethesda, MD 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Randomized Controlled Trials as Topic / methods*
Research Design*
Comment In:
J Clin Oncol. 2011 Feb 20;29(6):606-9   [PMID:  21172875 ]
J Clin Oncol. 2011 May 1;29(13):e390-2; author reply e393   [PMID:  21422433 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Excellent Outcome With Reduced Treatment in Infants With Nonmetastatic and Unresectable Neuroblastom...
Next Document:  Improved prognosis for older adolescents with acute lymphoblastic leukemia.